Q3 2023 13F Holders as of 9/30/2023
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
111M
-
Number of holders
-
168
-
Total 13F shares, excl. options
-
58.9M
-
Shares change
-
+5.14M
-
Total reported value, excl. options
-
$1.08B
-
Value change
-
+$85.4M
-
Put/Call ratio
-
0.74
-
Number of buys
-
100
-
Number of sells
-
-63
-
Price
-
$18.31
Significant Holders of Amylyx Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (AMLX) as of Q3 2023
208 filings reported holding AMLX - Amylyx Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share as of Q3 2023.
Amylyx Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (AMLX) has 168 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 58.9M shares
of 111M outstanding shares and own 53.19% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (5.05M shares), BlackRock Inc. (3.58M shares), VIKING GLOBAL INVESTORS LP (2.96M shares), PERCEPTIVE ADVISORS LLC (2.69M shares), Stonepine Capital Management, LLC (2.52M shares), MILLENNIUM MANAGEMENT LLC (2.12M shares), Boxer Capital, LLC (2.08M shares), Avidity Partners Management LP (1.76M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (1.7M shares), and Rock Springs Capital Management LP (1.55M shares).
This table shows the top 168 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.